Description
Semaglutide
Source: PubChem
CAS Number: 910463-68-2
Molecular Weight: 4113.58 g/mol
Sequence: H-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Lys-Gly-Ser-Ser-Glu-Leu-Ala-Lys-Gln-Glu-Gly-Leu-Gly-Cys-Thr-Cys-Thr-Gly-Lys-Lys-Leu-Leu-Arg-Leu-Tyr-Glu
Formula: C187H291N45O59
Product Overview
Semaglutide is a synthetic peptide that is widely researched for its role in glucose metabolism and potential effects on weight regulation in laboratory models. It is an analog of human glucagon-like peptide-1 (GLP-1) and has garnered interest in research settings for its effects on insulin secretion, appetite regulation, and glucose homeostasis in animal models.
Key Details:
- Physical Form: Lyophilized powder
- Solubility: Soluble in water
- Purity: ≥98% (by HPLC)
- Storage: Store in a dry, cool place, away from direct sunlight and moisture.
Research Application
Semaglutide is used in scientific research to explore its potential applications in glucose regulation, insulin sensitivity, and appetite control in controlled laboratory environments. It is not approved for human consumption or clinical use and is intended strictly for research purposes. Research into Semaglutide focuses on its mechanisms of action in glucose metabolism and related biological processes.
Disclaimer:
All products sold by Elite Miami Peptides are intended for laboratory research purposes only. Semaglutide is not classified as a prescription drug, supplement, or over-the-counter product. It is not intended for human use, therapeutic applications, or clinical treatment, and no health claims are made for this product. Semaglutide should not be used in humans or animals.
Compliance Notes:
This product adheres to advertising policies related to research peptides and complies with regulations that prohibit misleading health claims. Semaglutide is marketed solely for research purposes and does not exploit personal hardships or make claims related to its use in human health or therapeutic interventions.
Reviews
There are no reviews yet.